Novo Nordisk Tightens Its Belt, Cutting 9,000 Jobs And Its Profit Outlook

Novo Nordisk announced a significant restructuring, including the elimination of 9,000 jobs (11% of its workforce) to achieve 8 billion DKK ($1.26 billion) in annualized savings by 2026. This move, a response to increasing competition from knockoff versions of its blockbuster drugs Ozempic and Wegovy, accompanies the company's third guidance cut this year, with operating profit growth now projected at 4%-10% and sales growth at 8%-14%. While the new CEO, Mike Doustdar, aims to instill a performance-based culture and strengthen long-term positioning, analysts note that near-term profitability and growth expectations no longer significantly differentiate NVO from European peers, underscoring persistent challenges in its key obesity franchise.

Analysis

Novo Nordisk is undertaking a significant corporate restructuring, eliminating 9,000 jobs, or 11% of its workforce, in a bid to generate 8 billion Danish kroner ($1.26 billion) in annualized savings by 2026. This move is a direct response to mounting competitive pressure on its blockbuster obesity drugs, Ozempic and Wegovy, from lower-cost knockoff versions. The restructuring accompanies the company's third guidance reduction this year, a clear signal of deteriorating fundamentals. The operating profit growth outlook has been trimmed to 4%-10% from a previous 10%-16%, and the sales growth forecast is now 8%-14%, down from 16%-24%. This action, one of the first major initiatives by new CEO Mike Doustdar, underscores management's urgency to address the challenges that led to his predecessor's ouster. While the market saw a fractional stock price increase to 54.37, the broader context is highly negative; the stock has plummeted from a peak above 148 in June 2024 and holds an extremely poor Relative Strength Rating of 5. Analyst commentary suggests that while the cost-cutting may aid long-term positioning, Novo Nordisk's near-term growth and profitability premium over its European peers has been eroded.

Key Decisions for Investors

• Investors should re-evaluate their growth models for Novo Nordisk given the third guidance cut this year, as the company's near-term profitability premium relative to European pharma peers is now in question.
• Monitor the execution of the 8 billion DKK cost-saving plan and any stabilization in sales for the obesity franchise, as these will be key indicators of the new CEO's effectiveness in navigating competitive pressures.
• Given the stock's severe underperformance, reflected by a Relative Strength Rating of 5, consider the significant downside momentum and risk of further declines before anticipating a valuation-based recovery.